What are the limitations of the who 2022 icc 2022 aml?

While the who 2022 icc 2022 aml is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the who 2022 icc 2022 aml to ensure safe bedside use and optimal diagnostic accuracy.

How does the who 2022 icc 2022 aml compare to other Oncology scores?

The who 2022 icc 2022 aml is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the who 2022 icc 2022 aml free to use?

Yes. OpiCalc provides the who 2022 icc 2022 aml completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

WHO 2022 / ICC 2022 AML

Haematological Malignancies

Molecularly defined AML classification using key defining rearrangements and mutations.

PML::RARA

RUNX1::RUNX1T1

CBFB::MYH11

KMT2A rearrangement

DEK::NUP214

BCR::ABL1

NPM1 mutation

In-frame bZIP CEBPA mutation

TP53 mutation

Myelodysplasia-related gene mutation

Myelodysplasia-related cytogenetics

Calculated Interpretation

AML, NOS / requires integrated morphologic review

WHO 2022 / ICC 2022 classification is driven by defining molecular and cytogenetic lesions.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Molecularly defined AML classification using key defining rearrangements and mutations.

CLINICAL INSIGHT

How it Works

Clinical Inputs

PML::RARA

RUNX1::RUNX1T1

CBFB::MYH11

KMT2A rearrangement

DEK::NUP214

BCR::ABL1

NPM1 mutation

In-frame bZIP CEBPA mutation

TP53 mutation

Myelodysplasia-related gene mutation

Myelodysplasia-related cytogenetics

Interpretive Logic

Defining fusions and canonical mutations override morphology-only buckets.
Myelodysplasia-related AML is recognized by defining cytogenetic or gene features.
TP53-mutated AML is treated as a distinct high-risk biologic group.

CLINICAL INSIGHT

Practical Pearls

Result Bands

Fusion-defined AML

Mutation-defined AML

MR-AML

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Molecularly defined AML classification using key defining rearrangements and mutations.

OpiCalc Medical Oncology ModuleHaematological Malignancies2026

CLINICAL INSIGHT

Background

Context

WHO 2022 / ICC 2022 AML is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.

No clinical reference data available.

WHO 2022 / ICC 2022 AML

Haematological Malignancies

Molecularly defined AML classification using key defining rearrangements and mutations.

PML::RARA

RUNX1::RUNX1T1

CBFB::MYH11

KMT2A rearrangement

DEK::NUP214

BCR::ABL1

NPM1 mutation

In-frame bZIP CEBPA mutation

TP53 mutation

Myelodysplasia-related gene mutation

Myelodysplasia-related cytogenetics

Calculated Interpretation

AML, NOS / requires integrated morphologic review

WHO 2022 / ICC 2022 classification is driven by defining molecular and cytogenetic lesions.

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

Primary Use

Molecularly defined AML classification using key defining rearrangements and mutations.

CLINICAL INSIGHT

How it Works

Clinical Inputs

PML::RARA

RUNX1::RUNX1T1

CBFB::MYH11

KMT2A rearrangement

DEK::NUP214

BCR::ABL1

NPM1 mutation

In-frame bZIP CEBPA mutation

TP53 mutation

Myelodysplasia-related gene mutation

Myelodysplasia-related cytogenetics

Interpretive Logic

Defining fusions and canonical mutations override morphology-only buckets.
Myelodysplasia-related AML is recognized by defining cytogenetic or gene features.
TP53-mutated AML is treated as a distinct high-risk biologic group.

CLINICAL INSIGHT

Practical Pearls

Result Bands

Fusion-defined AML

Mutation-defined AML

MR-AML

CLINICAL INSIGHT

Next Steps

Suggested Next Steps

Interpret the result in the full disease-specific clinical context.
Correlate with pathology, imaging, performance status, and multidisciplinary guidance.

CLINICAL INSIGHT

Evidence Base

Molecularly defined AML classification using key defining rearrangements and mutations.

OpiCalc Medical Oncology ModuleHaematological Malignancies2026

CLINICAL INSIGHT

Background

Context

WHO 2022 / ICC 2022 AML is included in the oncology module as a structured decision-support tool for haematological malignancies workflows.

No clinical reference data available.